Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction

British Journal of Pharmacology

Volumn 166, Issue 1, 2012, Pages 85-97

  Grammatopoulos, Dimitris K ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

alternative splicing; class B1 GPCRs; CRH; CRH R; MAPK; protein kinases; signalling; urocortin

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; UROCORTIN I; UROCORTIN II; UROCORTIN III;

ALTERNATIVE RNA SPLICING; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; ENZYME ACTIVATION; HUMAN; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; ANIMALS; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP; HUMANS; PHOSPHORYLATION; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RNA, MESSENGER; SIGNAL TRANSDUCTION; UROCORTINS;

EID: 84859713916     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01631.x     Document Type: Review

References (98)

1. Aggelidou E, Hillhouse EW, Grammatopoulos DK, (2002). Up-regulation of nitric oxide synthase and modulation of the guanylate cyclase activity by corticotropin-releasing hormone but not urocortin II or urocortin III in cultured human pregnant myometrial cells. Proc Natl Acad Sci USA 99: 3300-3305.
2. Assil IQ, Qi LJ, Arai M, Shomali M, Abou-Samra AB, (2001). Juxtamembrane region of the amino terminus of the corticotropin releasing factor receptor type 1 is important for ligand interaction. Biochemistry 40: 1187-1195.
3. Audsley N, Kay I, Hayes TK, Coast GM, (1995). Cross reactivity studies of CRF-related peptides on insect Malpighian tubules. Comp Biochem Physiol A Physiol 110: 87-93.
4. Bale TL, Vale WW, (2004). CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44: 525-557.
5. Bangasser DA, Curtis A, Reyes BA, Bethea TT, Parastatidis I, Ischiropoulos H, et al,. (2010). Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology. Mol Psychiatry 15: 896-904.
6. Berger H, Heinrich N, Wietfeld D, Bienert M, Beyermann M, (2006). Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain. Br J Pharmacol 149: 942-947.
7. Beyermann M, Heinrich N, Fechner K, Furkert J, Zhang W, Kraetke O, et al,. (2007). Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain. Br J Pharmacol 151: 851-859.
8. Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, et al,. (2004a). Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 145: 24-35.
9. Brar BK, Chen A, Perrin MH, Vale W, (2004b). Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology 145: 1718-1729.
10. Cantarella G, Lempereur L, Lombardo G, Chiarenza A, Pafumi C, Zappala G, et al,. (2001). Divergent effects of corticotropin releasing hormone on endothelial cell nitric oxide synthase are associated with different expression of CRH type 1 and 2 receptors. Br J Pharmacol 134: 837-844.
11. Chang CL, Hsu SY, (2004). Ancient evolution of stress-regulating peptides in vertebrates. Peptides 25: 1681-1688.
12. Chen AM, Perrin MH, Digruccio MR, Vaughan JM, Brar BK, Arias CM, et al,. (2005). A soluble mouse brain splice variant of type 2alpha corticotropin- releasing factor (CRF) receptor binds ligands and modulates their activity. Proc Natl Acad Sci USA 102: 2620-2625.
13. Chen R, Lewis KA, Perrin MH, Vale WW, (1993). Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 90: 8967-8971.
14. Dautzenberg FM, Wille S, Braun S, Hauger RL, (2002). GRK3 regulation during CRF- and urocortin-induced CRF1 receptor desensitization. Biochem Biophys Res Commun 298: 303-308.
15. Denver RJ, (1997). Environmental stress as a developmental cue: corticotropin-releasing hormone is a proximate mediator of adaptive phenotypic plasticity in amphibian metamorphosis. Horm Behav 31: 169-179.
16. Dermitzaki E, Tsatsanis C, Gravanis A, Margioris AN, (2002). Corticotropin-releasing hormone (CRH) induces Fas ligand production and apoptosis in PC12 cells via activation of p38 MAPK. J Biol Chem 277: 12280-12287.
17. Elliott-Hunt CR, Kazlauskaite J, Wilde GJC, Grammatopoulos D, Hillhouse EW, (2002). Potential signalling pathways underlying corticotropin-releasing hormone's mediated neuroprotection from excitotoxicity in rat hippocampus. J Neurochem 80: 416-425.
18. Facci L, Stevens DA, Pangallo M, Franceschini D, Skaper SD, Strijbos PJ, (2003). Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors. Neuropharmacology 45: 623-636.
19. Gkountelias K, Tselios T, Venihaki M, Deraos G, Lazaridis I, Rassouli O, et al,. (2009). Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding. Mol Pharmacol 75: 793-800.
20. Grace CR, Perrin MH, DiGruccio MR, Miller CL, Rivier JE, Vale WW, et al,. (2004). NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proc Natl Acad Sci USA 101: 12836-12841.
21. Grace CR, Perrin MH, Gulyas J, Digruccio MR, Cantle JP, Rivier JE, et al,. (2007). Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand. Proc Natl Acad Sci USA 104: 4858-4863.
22. Grace CR, Perrin MH, Gulyas J, Rivier JE, Vale WW, Riek R, (2010). NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist. J Biol Chem 285: 38580-38589.
23. Grammatopoulos D, Hillhouse EW, (1999). Activation of protein kinase C by oxytocin inhibits the biological activity of the human myometrial CRH receptor at term. Endocrinology 140: 585-594.
24. Grammatopoulos DK, Dai Y, Randeva HS, Levine MA, Karteris E, Easton AJ, et al,. (1999). A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes. Mol Endocrinol 13: 2189-2202.
25. Grammatopoulos DK, Randeva HS, Levine MA, Katsanou ES, Hillhouse EW, (2000). Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins. Mol Endocrinol 14: 2076-2091.
26. Grammatopoulos DK, Randeva HS, Levine MA, Kanellopoulou KA, Hillhouse EW, (2001). Rat cerebral cortex corticotropin-releasing hormone receptors: evidence for receptor coupling to multiple G-proteins. J Neurochem 76: 509-519.
27. Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G, et al,. (2002). CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 143: 807-813.
28. Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, et al,. (2007). Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol 264: 44-49.
29. Haug T, Storm JF, (2000). Protein kinase A mediates the modulation of the slow Ca(2+)-dependent K(+) current, I(sAHP), by the neuropeptides CRF, VIP, and CGRP in hippocampal pyramidal neurons. J Neurophysiol 83: 2071-2079.
30. Hauger RL, Smith RD, Braun S, Dautzenberg FM, Catt KJ, (2000). Rapid agonist-induced phosphorylation of the human CRF receptor, type 1: a potential mechanism for homologous desensitization. Biochem Biophys Res Commun 268: 572-576.
31. Hauger RL, Olivares-Reyes JA, Braun S, Catt KJ, Dautzenberg FM, (2003). Mediation of corticotropin releasing factor type 1 receptor phosphorylation and desensitization by protein kinase C: a possible role in stress adaptation. J Pharmacol Exp Ther 306: 794-803.
32. Hillhouse EW, Grammatopoulos DK, (2006). The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 27: 260-286.
33. Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, et al,. (2004). Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists. Biochemistry 43: 3996-4011.
34. Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE, (2005). Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity. Peptides 26: 457-470.
35. Hoare SR, Fleck BA, Gross RS, Crowe PD, Williams JP, Grigoriadis DE, (2008). Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation. Mol Pharmacol 73: 1371-1380.
36. Holmes KD, Babwah AV, Dale LB, Poulter MO, Ferguson SS, (2006). Differential regulation of corticotropin releasing factor 1alpha receptor endocytosis and trafficking by beta-arrestins and Rab GTPases. J Neurochem 96: 934-949.
37. Hsu SY, Hsueh AJ, (2001). Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7: 605-611.
38. Huang M, Kempuraj D, Papadopoulou N, Kourelis T, Donelan J, Manola A, et al,. (2009). Urocortin induces interleukin-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-kappaB activation. J Mol Endocrinol 42: 397-405.
39. Jahn O, Tezval H, van Werven L, Eckart K, Spiess J, (2004). Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity. Neuropharmacology 47: 233-242.
40. Jin D, He P, You X, Zhu X, Dai L, He Q, et al,. (2007). Expression of corticotropin-releasing hormone receptor type 1 and type 2 in human pregnant myometrium. Reprod Sci 14: 568-577.
41. Kageyama K, Hanada K, Moriyama T, Nigawara T, Sakihara S, Suda T, (2006). G protein-coupled receptor kinase 2 involvement in desensitization of corticotropin-releasing factor (CRF) receptor type 1 by CRF in murine corticotrophs. Endocrinology 147: 441-450.
42. Karalis KP, Venihaki M, Zhao J, van Vlerken LE, Chandras C, (2004). NF-kappaB participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene. J Biol Chem 279: 10837-10840.
43. Karteris E, Grammatopoulos D, Randeva H, Hillhouse EW, (2000). Signal transduction characteristics of the corticotropin-releasing hormone receptors in the feto-placental unit. J Clin Endocrinol Metab 85: 1989-1996.
44. Karteris E, Vatish M, Hillhouse EW, Grammatopoulos DK, (2005). Preeclampsia is associated with impaired regulation of the placental nitric oxide-cyclic guanosine monophosphate pathway by corticotropin-releasing hormone (CRH) and CRH-related peptides. J Clin Endocrinol Metab 90: 3680-3687.
45. Karteris E, Markovic D, Chen J, Hillhouse EW, Grammatopoulos DK, (2010). Identification of a novel corticotropin-releasing hormone type 1beta-like receptor variant lacking exon 13 in human pregnant myometrium regulated by estradiol-17beta and progesterone. Endocrinology 151: 4959-4968.
46. Khattak MN, Buchfelder M, Kleindienst A, Schöfl C, Kremenevskaja N, (2010). CRH and SRIF have opposite effects on the Wnt/β-catenin signalling pathway through PKA/GSK-3β in corticotroph pituitary cells. Cancer Invest 28: 797-805.
47. Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA, et al,. (2002). Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol 16: 1638-1651.
48. Ladds G, Davis K, Hillhouse EW, Davey J, (2003). Modified yeast cells to investigate the coupling of G protein-coupled receptors to specific G proteins. Mol Microbiol 47: 781-792.
49. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, et al,. (2001). Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98: 7570-7555.
50. Lezoualc'h F, Engert S, Berning B, Behl C, (2000). Corticotropin- releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. Mol Endocrinol 14: 147-159.
51. Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, Maki RA, (1997a). Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol 11: 2048-2053.
52. Liaw CW, Grigoriadis DE, Lovenberg TW, De Souza EB, Maki RA, (1997b). Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach. Mol Endocrinol 11: 980-985.
53. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, et al,. (1995). Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 92: 836-840.
54. Markovic D, Grammatopoulos DK, (2009). Focus on the splicing of secretin GPCRs transmembrane-domain 7. Trends Biochem Sci 34: 443-452.
55. Markovic D, Papadopoulou N, Teli T, Randeva H, Levine MA, Hillhouse EW, et al,. (2006). Differential responses of corticotropin-releasing hormone receptor type 1 variants to protein kinase C phosphorylation. J Pharmacol Exp Ther 319: 1032-1042.
56. Markovic D, Lehnert H, Levine MA, Grammatopoulos DK, (2008a). Structural determinants critical for localization and signaling within the seventh transmembrane domain of the type 1 corticotropin releasing hormone receptor: lessons from the receptor variant R1d. Mol Endocrinol 22: 2505-2519.
57. Markovic D, Punn A, Lehnert H, Grammatopoulos DK, (2008b). Intracellular mechanisms regulating corticotropin-releasing hormone receptor-2beta endocytosis and interaction with extracellularly regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling cascades. Mol Endocrinol 22: 689-706.
58. Markovic D, Punn A, Lehnert H, Grammatopoulos DK, (2011). Molecular determinants and feedback circuits regulating type 2 CRH receptor signal integration. Biochim Biophys Acta Mol Cell Res 1813: 896-907.
59. Mazur AW, Wang F, Tcheiner M, Donnelly E, Isfort RJ, (2004). Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides. J Med Chem 47: 3450-3454.
60. Nemoto T, Mano-Otagiri A, Shibasaki T, (2005). Urocortin 2 induces tyrosine hydroxylase phosphorylation in PC12 cells. Biochem Biophys Res Commun 330: 821-831.
61. Nielsen SM, Nielsen LZ, Hjorth SA, Perrin MH, Vale WW, (2000). Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras. Proc Natl Acad Sci USA 97: 10277-10281.
62. Nordstrom KJ, Lagerstrom MC, Waller LM, Fredriksson R, Schioth HB, (2009). The secretin GPCRs descended from the family of adhesion GPCRs. Mol Biol Evol 26: 71-84.
63. Oakley RH, Olivares-Reyes JA, Hudson CC, Flores-Vega F, Dautzenberg FM, Hauger RL, (2007). Carboxyl-terminal and intracellular loop sites for CRF1 receptor phosphorylation and beta-arrestin-2 recruitment: a mechanism regulating stress and anxiety responses. Am J Physiol Regul Integr Comp Physiol 293: R209-R222.
64. Pal K, Swaminathan K, Xu HE, Pioszak AA, (2010). Structural basis for hormone recognition by the human CRFR2{alpha} G protein-coupled receptor. J Biol Chem 285: 40351-40361.
65. Papadopoulou N, Chen J, Randeva H, Levine MA, Hillhouse EW, Grammatopoulos D, (2004). Protein kinase A-induced negative regulation of the corticotropin-releasing hormone (CRH) R1α receptor-ERK signal transduction pathway: the critical role of Ser301 for signalling switch and selectivity. Mol Endocrinol 18: 624-639.
66. Park HJ, Kim HJ, Lee JH, Lee JY, Cho BK, Kang JS, et al,. (2005). Corticotropin-releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of p38 mitogen-activated protein kinase (MAPK) pathway. J Invest Dermatol 124: 751-755.
67. Pedersen WA, Wan R, Zhang P, Mattson MP, (2002). Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. J Neurosci 22: 404-412.
68. Perrin MH, Sutton S, Bain DL, Berggren WT, Vale WW, (1998). The first extracellular domain of corticotropin releasing factor-R1 contains major binding determinants for urocortin and astressin. Endocrinology 13: 566-570.
69. Perry SJ, Junger S, Kohout TA, Hoare SRJ, Struthers RS, Grigoriadis DE, et al,. (2005). Distinct conformations of the corticotropin releasing factor type 1 receptor adopted following agonist and antagonist binding are differentially regulated. J Biol Chem 280: 11560-11568.
70. Pierce KL, Luttrell LM, Lefkowitz RJ, (2001). New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20: 1532-1539.
71. Pioszak AA, Parker NR, Suino-Powell K, Xu HE, (2008). Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1. J Biol Chem 283: 32900-32912.
72. Punn A, Levine MA, Grammatopoulos DK, (2006). Identification of signaling molecules mediating corticotropin-releasing hormone-R1alpha-mitogen-activated protein kinase (MAPK) interactions: the critical role of phosphatidylinositol 3-kinase in regulating ERK1/2 but not p38 MAPK activation. Mol Endocrinol 20: 3179-3195.
73. Radulovic M, Hippel C, Spiess J, (2003). Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases. J Neurochem 84: 1074-1085.
74. Ralph JA, Zocco D, Bresnihan B, Fitzgerald O, McEvoy AN, Murphy EP, (2007). A role for type 1alpha corticotropin-releasing hormone receptors in mediating local changes in chronically inflamed tissue. Am J Pathol 170: 1121-1133.
75. Rasmussen TN, Novak I, Nielsen SM, (2004). Internalization of the human CRF receptor 1 is independent of classical phosphorylation sites and of beta-arrestin 1 recruitment. Eur J Biochem 271: 4366-4374.
76. Reisine T, Rougon G, Barbet J, Affolter HU, (1985). Corticotropin- releasing factor-induced adrenocorticotropin hormone release and synthesis is blocked by incorporation of the inhibitor of cyclic AMP-dependent protein kinase into anterior pituitary tumor cells by liposomes. Proc Natl Acad Sci USA 82: 8261-8265.
77. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, et al,. (2001). Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98: 2843-2848.
78. Rivier J, Gulyas J, Kirby D, Low W, Perrin MH, Kunitake K, et al,. (2002). Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 45: 4737-4747.
79. Ruhmann A, Bonk I, Lin CR, Rosenfeld MG, Spiess J, (1998). Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci USA 95: 15264-15269.
80. Sananbenesi F, Fischer A, Schrick C, Spiess J, Radulovic J, (2003). Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotropin-releasing factor receptor 2: a possible link between stress and fear memory. J Neurosci 23: 11436-11443.
81. Shaywitz AJ, Greenberg ME, (1999). CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68: 821-861.
82. Suda T, Kageyama K, Sakihara S, Nigawara T, (2004). Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors. Peptides 25: 1689-1701.
83. Sydow S, Flaccus A, Fischer A, Spiess J, (1999). The role of the fourth extracellular domain of the rat corticotropin-releasing factor receptor type 1 in ligand binding. Eur J Biochem 259: 55-62.
84. Sztainberg Y, Kuperman Y, Issler O, Gil S, Vaughan J, Rivier J, et al,. (2009). A novel corticotropin-releasing factor receptor splice variant exhibits dominant negative activity: a putative link to stress-induced heart disease. FASEB J 23: 2186-2196.
85. Teli T, Markovic D, Levine MA, Hillhouse EW, Grammatopoulos DK, (2005). Regulation of corticotropin-releasing hormone receptor type 1alpha signaling: structural determinants for G protein-coupled receptor kinase-mediated phosphorylation and agonist-mediated desensitization. Mol Endocrinol 19: 474-490.
86. Teli T, Markovic D, Hewitt ME, Levine MA, Hillhouse EW, Grammatopoulos DK, (2008). Structural domains determining signalling characteristics of the CRH-receptor type 1 variant R1beta and response to PKC phosphorylation. Cell Signal 20: 40-49.
87. Ulisse S, Fabbri A, Dufau ML, (1989). Corticotropin-releasing factor receptors and actions in rat Leydig cells. J Biol Chem 264: 2156-2163.
88. Van Kolen K, Dautzenberg FM, Verstraeten K, Royaux I, De Hoogt R, Gutknecht E, et al,. (2010). Corticotropin releasing factor-induced ERK phosphorylation in AtT20 cells occurs via a cAMP-dependent mechanism requiring EPAC2. Neuropharmacology 58: 135-144.
89. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, et al,. (1995). Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378: 287-292.
90. Wietfeld D, Heinrich N, Furkert J, Fechner K, Beyermann M, Bienert M, et al,. (2004). Regulation of the coupling to different G proteins of rat corticotropin-releasing factor receptor type 1 in human embryonic kidney 293 cells. J Biol Chem 279: 38386-38394.
91. Wille S, Sydow S, Palchaudhuri MR, Spiess J, Dautzenberg FM, (1999). Identification of amino acids in the N-terminal domain of corticotropin- releasing factor receptor 1 that are important determinants of high-affinity ligand binding. J Neurochem 72: 388-395.
92. Wu SV, Yuan PQ, Wang L, Peng YL, Chen CY, Taché Y, (2007). Identification and characterization of multiple corticotropin-releasing factor type 2 receptor isoforms in the rat esophagus. Endocrinology 148: 1675-1687.
93. Wu Y, Zhang R, Zhou C, Xu Y, Guan X, Hu J, et al,. (2009). Enhanced expression of vascular cell adhesion molecule-1 by corticotrophin-releasing hormone contributes to progression of atherosclerosis in LDL receptor-deficient mice. Atherosclerosis 203: 360-370.
94. Xiong Y, Xie LY, Abou-Samra AB, (1995). Signaling properties of mouse and human corticotropin-releasing factor (CRF) receptors: decreased coupling efficiency of human type II CRF receptor. Endocrinology 136: 1828-1834.
95. Zbytek B, Pfeffer LM, Slominski AT, (2006). CRH inhibits NF-kappa B signaling in human melanocytes. Peptides 27: 3276-3283.
96. Zhao J, Karalis KP, (2002). Regulation of nuclear factor-kappaB by corticotropin-releasing hormone in mouse thymocytes. Mol Endocrinol 16: 2561-2570.
97. Zmijewski MA, Slominski AT, (2009a). CRF1 receptor splicing in epidermal keratinocytes: potential biological role and environmental regulations. J Cell Physiol 218: 593-602.
98. Zmijewski MA, Slominski AT, (2009b). Modulation of corticotropin releasing factor (CRF) signaling through receptor splicing in mouse pituitary cell line AtT-20-emerging role of soluble isoforms. J Physiol Pharmacol 60: 39-46.